Abstract
TLRs are very important players to regulate innate immune responses. TLR4 controls the host defense by sensing an exotic pathogen, such as lipopolysaccharides. At the same time, some endogenous proteins, including HMGB1 and S100A8, could also function to be a ligand to elicit inflammatory reactions. These facts make TLR4 signaling system very complicated. For instance, the application of TLR4 ligands in cancer therapies is desirable for enhancement of anti-tumor immunity in terms of its reparative nature, but undesirable for enhancement of metastatic growth of cancer cells. In this manuscript, in order to make a novel molecular design to disrupt an interaction between TLR4/MD-2 and endogenous ligands, we provide a potential binding style of the TLR4/MD-2 complex with HMGB1 by using their 3D structural data and docking simulations, and also discuss S100A8 binding to TLR4/MD-2.
Keywords: Endogenous ligand, HMGB1, immunity, inflammatory, S100A8, TLR4/MD-2.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example
Volume: 15 Issue: 2
Author(s): Yoshiro Maru, Takeshi Tomita, Atsuko Deguchi, Katsuaki Ieguchi, Morichika Takita, Fujiko Tsukahara, Kazuhiro Takemura, Akio Kitao and Fabian Gusovsky
Affiliation:
Keywords: Endogenous ligand, HMGB1, immunity, inflammatory, S100A8, TLR4/MD-2.
Abstract: TLRs are very important players to regulate innate immune responses. TLR4 controls the host defense by sensing an exotic pathogen, such as lipopolysaccharides. At the same time, some endogenous proteins, including HMGB1 and S100A8, could also function to be a ligand to elicit inflammatory reactions. These facts make TLR4 signaling system very complicated. For instance, the application of TLR4 ligands in cancer therapies is desirable for enhancement of anti-tumor immunity in terms of its reparative nature, but undesirable for enhancement of metastatic growth of cancer cells. In this manuscript, in order to make a novel molecular design to disrupt an interaction between TLR4/MD-2 and endogenous ligands, we provide a potential binding style of the TLR4/MD-2 complex with HMGB1 by using their 3D structural data and docking simulations, and also discuss S100A8 binding to TLR4/MD-2.
Export Options
About this article
Cite this article as:
Maru Yoshiro, Tomita Takeshi, Deguchi Atsuko, Ieguchi Katsuaki, Takita Morichika, Tsukahara Fujiko, Takemura Kazuhiro, Kitao Akio and Gusovsky Fabian, Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15(2) . https://dx.doi.org/10.2174/187153031502150522123746
DOI https://dx.doi.org/10.2174/187153031502150522123746 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Exploring Signaling Pathways and Pancreatic Cancer Treatment Approaches Using Genetic Models
Mini-Reviews in Medicinal Chemistry Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Potential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Recent Patents on Anti-Cancer Drug Discovery Brain Tumor-Related Epilepsy
Current Neuropharmacology Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity
Letters in Drug Design & Discovery Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design On the Origin of Epidermal Cancers
Current Molecular Medicine Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Fructooligosaccharides of Edible Alliums: Occurrence, Chemistry and Health Benefits
Current Nutrition & Food Science Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Therapeutic Potential of Natural Compounds that Regulate the Activity of Protein Kinase C
Current Medicinal Chemistry Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Regulation of p53 Activity
Current Chemical Biology Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design